



RECEIVED #6/A
8/29/01
AUG 27 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
TECH CENTER 1600/2900

APPLICANT: Kolesnick <i>et al.</i>	§	ART UNIT:
	§	1647
FILED: July 17, 2000	§	
	§	EXAMINER:
SERIAL NO.: 09/554,980	§	Saoud, C.
	§	
FOR: Basic Fibroblast Growth Factor	§	DOCKET:
Treatment of Sepsis	§	D6049

The Assistant Commissioner of Patents and Trademarks
BOX NON-FEE AMENDMENT
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIRMENT AND AMENDMENT

Dear Sir:

In response to the Office Action mailed July 20, 2001,
please enter the following amendments and remarks.

AMENDMENTS

IN THE CLAIMS:

Please amend claim 4 as follows:

91 sub B1
4. (amended) A method of treating a
pathophysiological state characterized by endothelial apoptosis
resulting from increased generation of ceramide from sphingomyelin,